| Protocol |
Title |
| NSABP-B40 |
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens. |
| PACCT-1 |
(Program for the Assessment of Clinical Cancer Tests) - ER-Positive and/or PR-Positive Breast Cancer Axillary Node-Negative Candidate for Adjuvant Cytotoxic Therapy in Addition to Hormonal Therapy. |
| N0147 |
Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225)after Curative resection for Patients with Stage III Colon Cancer. |
| NSABP-B42 |
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Cancer. |
